Monday, October 14, 2019 - 1:00pm to 2:00pmDowntown Campus
We are genetically modifying CMV-specific T cells with anti-HIV CAR vectors to redirect the immune response towards HIV-infected cells. These bicistronic vectors express the CD4 extracellular domains to bind HIV Env, intracellular T cell signaling domains to activate cytotoxicity, and a membrane associated fusion inhibitor to protect the CAR Tc from infection. To increase the targeting of latent reservoirs, we are using the novel reactivation potential of adipose-derived mesenchymal stem cells.
For more information on the DTM Seminar Series please contact Dr. Patricia Scaraffia, email@example.com